CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
CASTLE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Dermatologic | $216.37M | $257.00M | $183.38M | $124.81M | $85.75M | $57.65M | 62.9% | -15.8% |
| Non-Dermatologic | $127.86M | $75.07M | $36.41M | $12.23M | – | – | 37.1% | +70.3% |
| Other | – | – | – | $12.23M | $8.33M | $5.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Castle Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.